|
Market Closed -
Nasdaq
16:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 6.370 USD | +0.63% |
|
-17.01% | -50.17% |
| 08-06 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 20.02 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -50.14% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 20.02 | 20.02 | 20.02 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -50.14% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1.45x | -7.08x | 10.6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | 0.1x | -0x |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.51x | 0.45x | 0.39x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.51x | 0.45x | 0.39x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -2.61x | -25.6x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.08x | -16.4x | 8.76x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -11.4 | -15 | -12.8 | -7.6 | -2.6 | -4.4 | -0.9 | 0.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.88 | 44.16 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.667 | -0.7823 | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -9.639 | -1.219 | 2.284 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -13.91 | -2.772 | 2.284 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 83.800 | 31.000 | 22.200 | 18.200 | 12.784 | 6.370 | 6.370 | 6.370 |
| Nbr of stocks (in thousands) | 2,174 | 2,182 | 2,611 | 2,734 | 3,140 | 3,142 | - | - |
| Announcement Date | 3/8/22 | 3/9/23 | 3/14/24 | 3/31/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.44x | - | - | - | 19.89M | |
| 30.1x | 5.32x | 20.41x | 0.3% | 224B | |
| 34.55x | 6.25x | 19.81x | 0.69% | 144B | |
| 38.28x | 10.06x | 22.2x | -.--% | 125B | |
| 16.97x | 3.46x | 11.28x | -.--% | 65.16B | |
| 19.22x | 2.31x | 11.61x | 2.65% | 50.05B | |
| 34.05x | 6.81x | 21.55x | -.--% | 49.67B | |
| 28.2x | 5.6x | 19.02x | 0.71% | 40.81B | |
| 70.87x | 6.77x | 20.65x | -.--% | 39.77B | |
| 41.45x | 6.67x | 23.57x | -.--% | 30.96B | |
| Average | 31.23x | 5.92x | 18.90x | 0.48% | 76.92B | |
| Weighted average by Cap. | 33.16x | 6.15x | 19.38x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
